Results 211 to 220 of about 205,861 (285)
Cost-Effectiveness of Maintaining Higher Stem-Cell Collection Thresholds in the Chimeric Antigen Receptor T-Cell Era for Multiple Myeloma. [PDF]
Malek E +6 more
europepmc +1 more source
ABSTRACT Primary refractory Diffuse Large B‐Cell Lymphoma is associated with poor outcomes and limited responsiveness to conventional salvage therapies. Although CAR T‐cell therapy represents the standard of care in this setting, a substantial proportion of patients cannot receive it despite meeting disease‐related criteria. In this review, “unsuitable”
Santino Caserta +12 more
wiley +1 more source
Propylthiouracil Induced Neutropenia in Thyroid Storm: A Case Requiring Urgent Total Thyroidectomy. [PDF]
Aljishi AK +5 more
europepmc +1 more source
ABSTRACT Modern therapies have clearly marked the history of multiple myeloma (MM), leading to undisputed advantages in terms of sustained responses and prolonged survival, while progressively improving patients' quality of life. Nonetheless, disease recurrence and resistance to available therapies underscore the importance of identifying additional ...
K. Mancuso +18 more
wiley +1 more source
Tamoxifen-induced neutropenia and leukopenia in a breast cancer patient: a case report and literature review. [PDF]
Liu C, Xu F, Liu Q.
europepmc +1 more source
Postoperative Care and Management in Pediatric Hematology‐Oncology Patients
ABSTRACT Pediatric patients with hematologic and oncologic diseases often undergo surgical procedures as part of diagnosis and therapy. These include central venous catheter placements, tumor resections, lymph node and bone marrow biopsies, among others.
Shachi Srivatsa, Sara A. Mansfield
wiley +1 more source
Risk signals and clinical characteristics of serious adverse events of neutropenia associated with pembrolizumab: a FAERS database study. [PDF]
Niu J, Xu S.
europepmc +1 more source
Giant cellulitis‐like Sweet's syndrome induced by gilteritinib
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Juan de Luque‐Fernández +5 more
wiley +1 more source
ABSTRACT Relapsed and refractory multiple myeloma (RRMM) remains associated with poor outcomes, particularly in patients exposed or refractory to proteasome inhibitors, immunomodulatory agents, and anti‐CD38 monoclonal antibodies. Targeting B‐cell maturation antigen (BCMA) has emerged as an effective therapeutic strategy, prompting the development of ...
Maria Eugenia Alvaro +12 more
wiley +1 more source

